| NCT ID | NCT06893328 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wei Chen |
| Condition | Primary Membranous Nephropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-11 |
| Primary Completion | 2027-11-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-11-11 with a primary completion date of 2027-11-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous nephropathy. At the same time, the investigators conducted a real-world study on patients who did not meet the inclusion and exclusion criteria or were unwilling to enter the RCT cohort, to further observe the trial results in a broader population.
Eligibility Criteria
Inclusion Criteria: 1\. Diagnosed as primary membranous nephropathy (PMN) by renal biopsy; 2. Aged over 18 years; 3. An average 24-hour urine protein ≥ 3.5g twice a week after treatment with ACE inhibitors or ARBs for at least 3 months. \- Exclusion Criteria: 1. With secondary membranous nephropathy (such as hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes); 2. Active infection, such as active hepatitis B or hepatitis C, tuberculosis (evidence of active tuberculosis infection within 1 year), or human immunodeficiency virus HIV infection (positive for anti-HIV antibodies), etc. 3. A history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or organ transplantation. \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06893328 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Membranous Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06893328 currently recruiting?
Yes, NCT06893328 is actively recruiting participants. Contact the research team at chenwei99@mail.sysu.edu.cn for enrollment information.
Where is the NCT06893328 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06893328 clinical trial?
NCT06893328 is sponsored by Wei Chen. The trial plans to enroll 200 participants.